Sun, Apr 20, 2014, 3:59 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • palatine123 palatine123 Aug 17, 2013 7:57 AM Flag

    Lower IMS and Symphony script count

    I believe these factors were involved for this trend:

    1) Few dieting in the summer.
    2) Only 200 reps.
    3) Limited insurance coverage.
    4) Limited awareness by general public or doctors.
    5) Easi seems to be taking a conservative approach to roll-out.

    I things will change starting in 2014:

    1) Increased insurance coverage.
    2) Increased awareness thru DTC, social media and word of mouth.
    3) Doctor's being educated about Belviq through reps, conferences and dinner presentations.
    4) PCP doctors more comfortable about prescribing since Belviq will be on the market for 9-10 months.
    5) Science rules in the end.

    We know that Belviq works not only for weight reduction but for lower A1C levels! It seems we are hearing about most responders than previously thought.

    Shorts will take advantage of the initial script numbers. I believe this will end in a few months.
    I am holding my shares for the future!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Have ya heard the term "time heals all"? Well it applies to drug commerializations when ya got a good drug. Well we got a good drug and giant markets and time here has barely begun to march on! Your first four reasons contribute a bit to any rollout of a ne med. Your fifth is not likely true--its just a step-by-step process thats going slowly only in investors minds.

      Regarding your changes, they will continue to evolve even this year and really proliferate next year.

      JMO

      Kutz

      Sentiment: Strong Buy

 
ARNA
6.18-0.12(-1.90%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.